CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer

Maeda, Satoshi; Shinchi, Hiroyuki; Kurahara, Hiroshi; Mataki, Yuko; Maemura, Kousei; Sato, Masami; Aikou, Takashi; Takao, Sonshin

doi:10.1038/sj.bjc.6604307

Cited by 190 publications

(164 citation statements)

References 54 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…Taken together, the specificity of our results is supported by previous studies in colorectal cancer. However, staining results, which differ from the positivity of the luminal surface in colorectal cancer, have recently been reported in pancreatic cancer, where a cytoplasmic expression of CD133 was shown (Hermann et al, 2007;Maeda et al, 2008). Such organspecific patterns of CD133 expression still have to be clarified in further studies.…”

Section: Discussionmentioning

confidence: 98%

CD133 expression is an independent prognostic marker for low survival in colorectal cancer

et al. 2008

View full text Add to dashboard Cite

Colon cancer cells have previously been demonstrated to contain a subpopulation of CD133 þ tumour cells that have the ability to initiate tumour growth and are thus referred to as colon cancer-initiating cells or colon cancer stem cells (CSCs). As CD133 is currently one of the best markers to characterise colon CSCs, we analysed CD133 þ tumour cells in colorectal cancer specimens using immunohistochemistry. We show that CD133 detection is specific and that the CD133 antigen is localised on the glandularluminal surface of colon cancer cells, whereas undifferentiated tumour cells at the front of invasion are CD133À. In addition, CD133 þ cells are characterised in situ by lack of CK20 expression, whereas they are positive for EpCAM. Moreover, we show that CD133 expression in colorectal cancer is an independent prognostic marker that correlates with low survival in a stratified patient collective. Our results indicate that in colorectal cancer, the CD133 þ tumour cells can be detected by immunohistochemistry, which facilitates their further characterisation in situ.

show abstract

Section: Discussionmentioning

confidence: 98%

CD133 expression is an independent prognostic marker for low survival in colorectal cancer

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Hermann et al reported that CD133+ cells were dramatically more resistant to gemcitabine and had highly tumorigenic and metastatic features [13]. In addition, it was shown that CD133 had significant role in prognosis of PDAC [46]. It was observed that the 5-year survival rate of patients with CD133-negative tumors was almost 5-fold higher than patients with less than 5% CD133-positive cells.…”

Section: Cd133mentioning

confidence: 76%

Pancreatic Ductal Adenocarcinoma Stem Cells

Aghamaliyev¹,

Birgin²,

Rückert³

2015

Pancreat Disord Ther

View full text Add to dashboard Cite

show abstract

“…Pancreatic CSCs with CD133 expression demonstrated a higher metastatic potential compared with those without it (9). Stem cell-like glioma cells with CD133 expression promoted tumor angiogenesis has been reported to be associated with metastatic potential and poor survival in certain human malignancies (11,12). Vascular endothelial growth factor (VEGF) is intimately involved in the regulation of tumor-associated angiogenesis and has been reported to be associated with tumor aggressiveness, metastasis and poor prognosis (13).…”

Section: Introductionmentioning

confidence: 99%

Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer

Tanaka¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. CD133 has been postulated to be a colon cancer stem cell (CSCs) marker. Recent investigations suggest that CSCs might contribute to cancer recurrence and resistance to conventional therapies. This study aimed to evaluate the role of CD133 in residual cancer cells after chemoradiotherapy (CRT) for rectal cancer. Forty patients with rectal cancer underwent CRT followed by surgery. Total RNAs of rectal cancer cells before (n=30) and after (n=40) CRT were isolated. Intratumoral CD133, vascular endothelial growth factor (VEGF), and epidermal growth factor receptor (EGFR) levels were measured using real-time reverse transcription polymerase chain reaction. Immunohistochemical staining of CD133 after CRT was also investigated. CD133 in residual cancer cells was higher than in stromal cells in post-CRT specimens (p<0.0001). The levels of CD133 were found to have increased in post-CRT specimens (p=0.0184), while VEGF and EGFR levels decreased during CRT (p<0.0001 and p=0.0002, respectively). Patients who developed distant recurrence had a higher post-CRT CD133 compared with those patients without recurrence (p=0.0136). Elevated post-CRT CD133 was associated with poor disease-free survival (p=0.0168). Immunohistochemical staining of the cytoplasmic and apical/endoluminal membranous CD133 was observed in residual cancer cells after CRT. CD133 expression in residual cancer cells after CRT may indicate a treatment resistant phenotype in putative CSCs. Elevated CD133, but not VEGF or EGFR, on FFPE specimens may be a predictive marker of distant recurrence and poor survival after preoperative CRT in rectal cancer.

show abstract

CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer

Cited by 190 publications

References 54 publications

CD133 expression is an independent prognostic marker for low survival in colorectal cancer

CD133 expression is an independent prognostic marker for low survival in colorectal cancer

Pancreatic Ductal Adenocarcinoma Stem Cells

Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer

Contact Info

Product

Resources

About